Is Jefferies Positive On Shares of Vanda Pharmaceuticals (NASDAQ:VNDA)?

November 9, 2018 - By Linda Rogers

Investors sentiment increased to 1.53 in 2018 Q2. Its up 0.57, from 0.96 in 2018Q1. It is positive, as 10 investors sold Vanda Pharmaceuticals Inc. shares while 33 reduced holdings. 18 funds opened positions while 48 raised stakes. 47.64 million shares or 3.78% more from 45.90 million shares in 2018Q1 were reported.

Hawk Ridge Cap Management Lp reported 258,877 shares. Millennium Mngmt owns 390,402 shares. Credit Suisse Ag stated it has 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). 41,000 are held by Cheyne Mgmt (Uk) Ltd Liability Partnership. Amer Century Inc holds 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) or 60,106 shares. Renaissance Techs Ltd holds 0.03% or 1.64 million shares. Ajo Ltd Partnership holds 0.01% or 72,805 shares. Virginia Retirement Et Al accumulated 39,600 shares. Dekabank Deutsche Girozentrale invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). State Of Wisconsin Board has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 52,300 shares. 2.17M were reported by State Street. Foundry Prns Ltd Limited Liability Company has 50,260 shares for 0.04% of their portfolio. Kistler holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 200 shares. Royal Comml Bank Of Canada holds 2,643 shares. American Gru Inc has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Why Has Jefferies Given Vanda Pharmaceuticals (NASDAQ:VNDA) a $26 Price Target

In analysts report issued on Thursday morning, stock analysts at Jefferies initiated coverage for Vanda Pharmaceuticals (NASDAQ:VNDA) shares. The firm has decided to set a Buy rating along with a $26, adding 10.83 % to the target.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 4 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Vanda Pharmaceuticals has $31 highest and $26 lowest target. $29’s average target is 23.61% above currents $23.46 stock price. Vanda Pharmaceuticals had 5 analyst reports since May 23, 2018 according to SRatingsIntel. As per Tuesday, October 16, the company rating was maintained by Citigroup. The rating was maintained by Oppenheimer with “Outperform” on Friday, September 21.

The stock increased 14.72% or $3.01 during the last trading session, reaching $23.46. About 1.94 million shares traded or 107.49% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 6.96% since November 9, 2017 and is uptrending. It has underperformed by 8.66% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $1.23 billion. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It has a 868.89 P/E ratio. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

More important recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Seekingalpha.com which released: “Vanda Pharma down 3% on FDA Warning Letter” on October 31, 2018, also Benzinga.com published article titled: “65 Stocks Moving In Thursday’s Mid-Day Session”, Gurufocus.com published: “Vanda Pharmaceuticals Announces Participation at November 2018 Investor Conferences” on November 09, 2018. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was released by: Seekingalpha.com and their article: “Vanda Pharmaceuticals, Inc. (VNDA) CEO Mihael Polymeropoulos on Q3 2018 Results – Earnings Call Transcript” with publication date: November 08, 2018.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>